Intrauterine administration of G-CSF, particularly during the ovulatory phase, is associated with a significant decrease in miscarriage risk and an enhancement in the likelihood of a successful pregnancy outcome in patients with a history of recurrent miscarriages. The gene discussed is CSF3; the disease is Miscarriage.